Here are four notes:
1. Among the analysts covering the stock, the 12-month price target is $87.88.
2. On Nov. 4, 2016, Zacks issued AmSurg shares a “hold” rating.
3. AmSurg reported earnings per share of $1.13 last quarter.
4. In the third quarter, AmSurg surpassed analysts’ estimates of $770.2 million and generated revenue of $822.2 million.
More articles on surgery centers:
Marshfield Clinic Health System facing opposition for $35M proposal featuring surgery center — 6 points
Analysts rate Surgery Partners shares — 4 things to know
BlackRock Institutional Trust Company lowers AmSurg stake by 0.2% — 5 quick facts
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
